Clinical trial NCT06505928: A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D
Official title: A Parallel-group, Randomized, Open-label Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Hepatitis D
Lead sponsor: Shanghai HEP Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2024-07-17
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a three-arm, parallel-group, randomized, open-label, delayed-controlled phase IIb clinical trial.
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to evaluate the efficacy and safety of L47 in the treatment of chronic hepatitis D. Patients with compensated CHD who satisfy the eligibility criteria are stratified by the presence or absence of liver cirrhosis and randomized into three groups at a 1:1:1 ratio. The subjects will receive continuous L47 (2.1 mg/d and 4.2 mg/d, s.c.) treatment for 48 weeks (groups A and B), or delayed treatment for 48 weeks (group C). Primary endpoint evaluation will be performed after the subjects complete the 48-week treatment.

Detailed description: This is a three-arm, parallel-group, randomized, open-label, delayed-controlled phase IIb clinical trial. Patients with compensated CHD who satisfy the eligibility criteria are stratified by the presence or absence of liver cirrhosis and randomized into the 2.1 mg group, 4.2 mg group, and delayed-treatment group at a 1:1:1 ratio . The subjects will receive continuous L47 (2.1 mg/d and 4.2 mg/d, s.c.) treatment for 48 weeks , or delayed treatment for 48 weeks (group C). The interim analysis will be performed after the subjects complete the 24-week treatment. Primary endpoint evaluation will be performed after the subjects complete the 48-week treatment.After the primary endpoint evaluation, each group will enter the 96-week extended treatment period. Groups A and B will continue to receive L47 treatment at the original doses; Group C will initiate L47 treatment (4.2 mg/day, s.c.) (Table 1.2). After the subjects have completed the extended treatment, each group will undergo off-treatment observation for 96 weeks.Throughout the study, subjects will be closely monitored and evaluated for safety, including adverse events (AEs).

Eligibility criteria: Inclusion Criteria:

* 1. Male or female subjects aged 18-65 years (both inclusive);
* 2. Subjects with positive HBsAg and/or HBV DNA for at least 6 months ("CHB");
* 3. Subjects with positive serum anti-HDV antibody before or at screening or with positive HDV RNA for at least 6 months before screening ("CHD");
* 4. Subjects with positive and quantifiable HDV RNA before enrollment;
* 5. 1 × ULN \< ALT \< 10 × ULN;
* 6. Subjects who should be treated with nucleoside/nucleotide reverse transcriptase inhibitors at enrollment or after enrollment according to the guidelines for the treatment of hepatitis D (compensated cirrhosis with detectable HBV DNA, or HBV DNA \> 2000 IU/mL in patients without cirrhosis) and consent to the use of entecavir for the treatment of chronic hepatitis B;
* 7. Subjects who do not plan a pregnancy within 3 years (women who are not pregnant or lactating, and males who agree to take effective contraceptive measures throughout the treatment period and for 3 months after the last dose);
* 8. Subjects exhibiting good compliance to the study protocol;
* 9. Subjects who understand the ICF and agree to sign it.

Exclusion Criteria:

* 1. Subjects suffering from severe decompensated liver fibrosis or decompensated liver cirrhosis with a Child-Pugh score \> 7;
* 2. Decompensated liver disease: Direct bilirubin \> 1.2 x ULN or prothrombin time \> 1.2 x ULN or serum albumin \< 35 g/L;
* 3. Abnormal hematology findings: White blood cell count (WBC) \< 3 × 109/L, neutrophil count \< 1.5 × 109/L or platelet count \< 60 × 109/L;
* 4. Creatinine clearance \< 60 mL/min;
* 5. Subjects who have any of the following conditions:

  1. History of current or past decompensated liver diseases (including coagulopathy, hepatic encephalopathy, and variceal bleeding);
  2. Comorbidity of underlying diseases such as severe infection, heart failure and chronic obstructive pulmonary disease, and other severe diseases;
  3. Diabetes mellitus and hypertension not effectively controlled (systolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 100 mmHg);
  4. Current or previous uncontrolled epilepsy or psychiatric disorders;
  5. History of solid organ transplantation;
  6. Evidence of active or suspected malignancies or history of malignancies, or untreated premalignant lesions within the past 5 years (except for successfully treated cervical carcinoma in situ at least 1 year before screening, and successfully treated basal cell carcinoma and squamous cell carcinoma \[≤ 3 cases of resected skin cancer within 5 years before screening \]), or history of liver cancer;
  7. History of alcohol abuse or drug addiction at present or within 6 months prior to participation in this study; 6. Subjects co-infected with hepatitis A, C, or E virus or with uncontrolled HIV co-infection (those with positive HCV antibody but negative HCV RNA at screening are eligible for enrollment. HIV-infected patients may be enrolled if cluster of differentiation 4 (CD4) cell count is \> 500/mL and HIV RNA is below the limit of detection for at least 12 months);
* 7. Presence of one or more other known primary or secondary liver diseases, such as alcoholism, autoimmune hepatitis, malignancies involving the liver, hemochromatosis, other congenital or metabolic diseases affecting the liver, congestive heart failure, or other serious cardiopulmonary diseases, excluding hepatitis B;
* 8. Subjects with one or more autoimmune diseases, immune-related extrahepatic manifestations (such as vasculitis, purpura, arteritis nodosa, peripheral neuropathy, and glomerulonephritis), or a history of requiring regular use of systemic corticosteroids (inhaled corticosteroids are allowed) or other immunosuppressive agents;
* 9. Subjects who have used interferon within 6 months before screening;
* 10. Subjects who have used L47 or Bulevirtide within 3 months;
* 11. Allergy to entecavir;
* 12. Pregnant or breastfeeding women;
* 13. Subjects who participated in other drug clinical trials within 30 days before randomization;
* 14. Subjects who are receiving prohibited treatment at screening that cannot be discontinued;
* 15. Subjects who cannot comply with the study protocol and complete all procedures as scheduled, or have significant abnormalities in other laboratory or auxiliary examinations, which render them ineligible for this trial.

Primary outcomes:
measure: compound response
timeFrame: Week 48
Secondary outcomes:
measure: HDV RNA below LLOQ
timeFrame: Week 48
measure: Decrease in HDV RNA by ≥ 2 log10 from baseline or undetectable HDV RNA
timeFrame: Week 48
measure: Decrease in HDV RNA from baseline
timeFrame: Week 48
measure: ALT normalization
timeFrame: Week 48
measure: Decrease in ALT from baseline
timeFrame: Week 48
measure: Changes in subjects' METAVIR system scores from baseline.
timeFrame: Week 48
measure: Change in fibrosis 4 (FIB-4) index from baseline
timeFrame: Week 48
measure: Change in Child-Pugh score from baseline
timeFrame: Week 48
measure: Change in Model for End-Stage Liver Disease (MELD) score from baseline
timeFrame: Week 48
measure: The incidence rate of Liver-related endpoint events.
timeFrame: Week 240
Other outcomes:
Locations:
city: Ulaanbaatar
country: Mongolia
facility: National cancer canter of Monglia
city: Ulaanbaatar
country: Mongolia
facility: National Center for Communicable Diseases
Study officials:
affiliation: National Cacer Center of Monglia
name: Oyunbileg Janchiv
role: PRINCIPAL_INVESTIGATOR
References: